Center for Genetic Engineering and Biotechnology | |
Type: | Research institute |
Preceding6: | --> |
Superseding6: | --> |
Headquarters: | Avenida 31 No. 15802, Havana, Cuba |
Coordinates: | 23.0738°N -82.4523°W |
Minister8 Name: | --> |
Deputyminister8 Name: | --> |
Chief9 Name: | --> |
Child25 Agency: | --> |
Keydocument6: | --> |
The Center for Genetic Engineering and Biotechnology (Spanish; Castilian: Centro de Ingeniería Genética y Biotecnología, CIGB) is a research institute in Havana, Cuba.
In 1982, the United Nations Industrial Development Organization (UNIDO) offered grant funding via a competitive application process to facilitate biotechnology development in the Third World. Cuba sought, but did not receive funding, which instead was awarded to a joint project proposed by India and Italy. Cuba nonetheless proceeded with the development of a biotechnology research institution using its own funds, CIGB.
In 2006, CIGB developed the Heberprot-P, which is used to treat foot ulcers.[1] Its use results in rapid wound healing and a 75% decrease in amputations among diabetics with foot ulcers.
As of 2017, CIGB had 1,600 employees and sold 21 products internationally.
As of 2020, CIGB had two joint ventures with China.[2]
It is responsible for creating the Abdala vaccine.[3] [4] [5]
The Centre developed the COVID-19 vaccine Mambisa, which is in the final stages of clinical trials.[6]